

Atezolizumab  
Essential medicine status  
General description

INN  
Atezolizumab  
ATC codes  
[L01XC18](#) [L01FF05](#)

Medicine type  
Biological agent

EML status history

Application rejected in 2019 ([TRS 1021](#)) for [Other specified malignant neoplasms of bronchus or lung](#)

Added in 2025 ([TRS 1064](#)) for [Other specified malignant neoplasms of bronchus or lung](#)

Application rejected in 2025 ([TRS 1064](#)) for [Adenocarcinoma of stomach](#)

Application rejected in 2025 ([TRS 1064](#)) for [Hepatocellular carcinoma of liver](#)

Therapeutic equivalent for

[pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#)

[pembrolizumab](#) for [Adenocarcinoma of stomach](#)

Wikipedia

[Atezolizumab](#)

DrugBank

[Atezolizumab](#)

Recommendations

Section

Immunomodulators

- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Hepatocellular carcinoma of liver](#)